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Abstract
Background: Chronic oral quercetin reduces blood pressure and restores endothelial dysfunction in hypertensive animals.
However, quercetin (aglycone) is usually not present in plasma, because it is rapidly metabolized into conjugated, mostly
inactive, metabolites. The aim of the study is to analyze whether deconjugation of these metabolites is involved in the
blood pressure lowering effect of quercetin.
Methodology/Principal Findings: We have analyzed the effects on blood pressure and vascular function in vitro of the
conjugated metabolites of quercetin (quercetin-3-glucuronide, Q3GA; isorhamnetin-3-glucuronide, I3GA; and quercetin-39-
sulfate, Q3’S) in spontaneously hypertensive rats (SHR). Q3GA and I3GA (1 mg/kg i.v.), but not Q3’S, progressively reduced
mean blood pressure (MBP), measured in conscious SHR. The hypotensive effect of Q3GA was abolished in SHR treated with
the specific inhibitor of b-glucuronidase, saccharic acid 1,4-lactone (SAL, 10 mg/ml). In mesenteric arteries, unlike quercetin,
Q3GA had no inhibitory effect in the contractile response to phenylephrine after 30 min of incubation. However, after
1 hour of incubation Q3GA strongly reduced this contractile response and this effect was prevented by SAL. Oral
administration of quercetin (10 mg/Kg) induced a progressive decrease in MBP, which was also suppressed by SAL.
Conclusions: Conjugated metabolites are involved in the in vivo antihypertensive effect of quercetin, acting as molecules
for the plasmatic transport of quercetin to the target tissues. Quercetin released from its glucuronidated metabolites could
be responsible for its vasorelaxant and hypotensive effect.
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Introduction
Flavonoids are polyphenolic compounds that occur ubiquitously
in plants and are consumed in the form of fruits, vegetables, nuts
and derived products such as wine and chocolate. The average
daily intake in the western diet of flavonols plus flavones (two main
classes of flavonoids) is estimated to be <23 mg, with quercetin
(3,39,49,5,7-pentahydroxyflavone) contributing 60–75% of the
total [1,2]. Quercetin is a prime example of such a flavonoid
group and it is found in foods bound to sugars, mainly as b-
glycosides. Quercetin glycosides occur in broccoli, apples, and
especially in onions, with an abundance as high as 0.25–0.5 g/kg
[3]. Prospective studies have shown an inverse correlation between
dietary flavonoid intake and mortality from coronary heart disease
[1,4]. Several studies using various animal models provide support
for the observed protective effects of dietary flavonoids with
respect to cardiovascular diseases [5]. For example, quercetin
exerts systemic and coronary vasodilatation and antiaggregant
effects in vitro [6–8] and reduces blood pressure, oxidative status
and end-organ damage in animal models of hypertension [9,10],
including spontaneously hypertensive rats (SHR) [9–12]. Chronic
quercetin also reduces blood pressure in stage 1 hypertensive
subjects [13]. However, there are not studies analyzing the acute
effects on blood pressure of oral quercetin.
Many previous in vitro studies have exposed tissues or cultured
cells to commercially available aglycones or the glycosylated
compounds which are present at extremely low concentrations in
plasma [14]. Upon ingestion with the diet, quercetin glycosides are
rapidly hydrolyzed during their passage across the small intestine
or by bacterial activity in the colon to generate quercetin aglycone.
Absorbed quercetin is rapidly conjugated with glucuronic acid
and/or sulfate during first-pass metabolism (intestine-liver) and a
portion of the metabolites are also methylated and, therefore, the
major metabolites of quercetin in rat and human plasma are
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isorhamnetin-3-glucuronide (I3GA) (Figure 1) while the aglycone
is usually undetectable [15–18]. The biological activity of
quercetin is generally attenuated after its conversion into the
metabolites. However, antioxidant activity for various quercetin
metabolites has been reported [19–21]. This may lead in vascular
beds to an improvement of endothelial function, while the
conjugated metabolites have no direct vasorelaxant effect in rat
aorta [21]. Moreover, injured/inflamed arteries, as occur in
hypertension and atherosclerosis, with activated macrophages are
potential targets of the metabolites of dietary quercetin [22]. Some
previous studies have shown that quercetin glucuronides can be
deconjugated in vitro in cultured macrophages [22] and in
homogenates from human liver and small intestine [23]. Q3GA
can be also slowly deconjugated within the vascular wall [24].
We hypothesized that the antihypertensive effects of quercetin
could be mediated by the conjugated derivatives that are present
in the circulating blood. These metabolites would reduce vascular
tone after deconjugation in the vascular tissue. Therefore, the aim
of the present study was to analyse the long term in vitro effects of
the main plasma quercetin conjugates in resistance mesenteric
arteries, their in vivo effects given intravenously on blood pressure
in SHR and the role of deconjugation via glucuronidase.
Moreover, we tested whether deconjugation is required for the
antihypertensive effects of oral quercetin aglycone.
Materials and Methods
Animals
All the experiments were performed in accordance with
Institutional Guidelines for the ethical care of animals, and ethic
committee of the University of Granada approved this study (ref.
2066/10). Twenty four-week old, male spontaneously hypertensive
rats (SHR) were obtained from Harlan Laboratories (Barcelona,
Spain). All rats were maintained five per cage at a constant
temperature (2461uC), with a 12-hour dark/light cycle and on
standard rat chow.
Blood pressure measurement
Direct blood pressure was measured in conscious SHR. For this
purpose, the rats were anaesthetised with 2.5 mL/kg i.p.
equitensin (500 mL contain 43% w/v chloral hydrate in 81 mL
ethanol; 4.86 mg pentobarbitone; 198 mL propylene glycol;
10.63 g MgSO4; distilled water) and the carotid artery was
cannulated to obtain direct measurements of arterial blood
pressure. The catheter was exteriorised through the skin on the
dorsal side of the neck and protected with a silver spring. A
cannula was also introduced into the left jugular vein for the
administration of quercetin metabolites and blood sampling. Upon
completion of the surgical procedure, rats were fasted and allowed
to recover for 6 h and, after connecting the catheter to a
transducer and a two-channel recorder (TRA-021 and Letigraph
2000, respectively; Letica SA, Barcelona, Spain), blood pressure
and heart rate (HR) were continuously recorded. Animals received
either Q3GA (0.2, 0.02 or 1 mg/kg), Q3’S or I3GA (1 mg/kg), or
drug vehicle (100 mL of phosphate buffered saline). The acute
effect of an oral dose of quercetin (10 mg/kg) administered by
gavage on blood pressure and heart rate were also analysed.
In another set of experiments, SHR rats were daily given i.p. for
3 days either isotonic solution (1 mL) or D-saccharic acid 1.4-
lactone (SAL), a specific inhibitor of beta-glucuronidase, (10 mg/
mL in 1 mL) [25] before the administration of the flavonoids.
Analysis of quercetin metabolites in rat plasma
Blood was collected into heparinized tubes and centrifuged. The
plasma samples (300 mL) were extracted with 300 mLo f
methanol/0.5 M acetic acid (80:20, v/v) for 30 min at 25uCi n
an ultrasonic bath, and then centrifuged for 3 min at 3500 g. The
supernatant was collected and the pellet was submitted to the same
process two further times assisted by sonication (1 min) using a
MicrosonTM ultrasonic cell disruptor (New York, USA). The
methanolic extracts were combined and dried in a centrifugal
concentrator micVac (GeneVac, Ipswich, United Kingdom). The
residue was dissolved in 120 mL acetonitrile/water (30:70 v/v) and
centrifuged (5 min, 3500 g) previous to its injection (100 mL) in the
HPLC-DAD-ESI/MS system.
Analyses were carried out in a Hewlett-Packard 1100
chromatograph (Agilent Technologies, Waldbronn, Germany)
with a quaternary pump and a DAD coupled to an HP Chem
Station (rev. A.05.04) data-processing station. An Ascentis
TM RP-
Amide 3 mm (2.16150 mm) column at 30uC was used. The
solvents used were: (A) 0.1% formic acid, and (B) acetonitrile. An
elution gradient was established from 15 to 50% B over 15 min,
isocratic 50% B for 10 min, from 50 to 75% B over 3 min,
isocratic 75% B for 10 min, and re-equilibration of the column, at
a flow rate of 0.2 mL/min. Double online detection was carried
out in the DAD using 370 nm as a preferred wavelength and in a
mass spectrometer connected to HPLC system via the DAD cell
outlet. MS detection was performed in an API 3200 Qtrap
(Applied Biosystems, Darmstadt, Germany) equipped with an ESI
source and a triple quadrupole-ion trap mass analyzer that was
controlled by the Analyst 5.1 software. Zero grade air served as the
nebulizer gas (30 psi) and turbo gas for solvent drying (400uC,
40 psi). Nitrogen served as the curtain (20 psi) and collision gas
(medium). The quadrupoles were set at unit resolution. The ion
spray voltage was set at 24500 V in the negative mode. Precursor
ion analysis was employed to detect all the precursor ions that
fragment to a common product ion (i.e., m/z 301 corresponding
to quercetin). Settings used were: declustering potential (DP)
240 V, entrance potential (EP) 210 V, collision energy (CE)
250 V, and cell exit potential 23 V. Enhanced product ion mode
was further performed in order to obtain the fragmentation
Figure 1. Structure of quercetin and its metabolites isorham-
netin, quercetin 3-glucuronide (Q3GA), isorhamnetin 3-glucu-
ronide (I3GA) and quercetin 39-sulfate (Q3’S).
doi:10.1371/journal.pone.0032673.g001
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experiment using the following parameters: DP 250 V, EP 26V ,
CE 225 V, and collision energy spread 0 V. Quantitative analysis
of the assayed flavonols and conjugated metabolites was performed
from their chromatographic peaks recorded at 370 nm by
comparison with calibration curves obtained by injection of
increasing concentrations of quercetin, I3GA, and Q3GA.
Vascular reactivity in vitro
SHR were stunned and killed by cervical dislocation. The
mesentery was removed and placed in cold Krebs solution
(composition in mmol/L: NaCl 118, KCl 4.75, NaHCO3 25,
MgSO4 1.2, CaCl2 2, KH2PO4 1.2, and glucose 11). Third-order
arteries were cleaned of surrounding fat and mounted in an
automated tension myograph (Danish Myotechnology, Denmark)
containing Krebs solution maintained at 37uC and gassed with 5%
CO2 in O2. After an equilibration period of 45 min, vessels were
normalized according to published protocols and vessel diameter
determined [26]. Following normalization, relaxation of phenyl-
ephrine (3 mM)-precontracted vessels to acetylcholine (Ach, 1 mM)
was used to determine endothelial integrity (vessels that relaxed by
at least 50% were considered endothelium-intact).
In order to analyze the effects on vascular function, in
endothelium-intact rings a concentration–response curve was
constructed by cumulative addition of phenylephrine (10
27–
10
24 M). Then vessels incubated in the absence or presence of
quercetin, isorhamnetin, Q3’S, Q3GA or I3GA (10 or 25 mM) for
30–120 min and a second concentration–response curve was
performed. In some arteries SAL (1 mM) was added 1 hour before
and during the incubation period with Q3GA.
b-glucuronidase activity
b-glucuronidase activity was measured by a colorimetric
analysis using phenolphthalein mono-b-glucuronide as the sub-
strate [22]. Briefly, 30 mg of protein of vascular mesenteric bed
homogenates from SHR were mixed with 0.6 mM phenolphtha-
lein mono-b-glucuronide in 100 mL of 0.1 mM sodium phosphate
buffer at pH 5. After incubation at 37uC for 30 min followed by
adding 200 mL of 0.1 M sodium phosphate buffer pH 11, the
absorbance at 540 nm indicating the formation of phenolphtha-
lein aglycone was measured. In some experiments, SAL (1 mM)
was added 1 hour before phenolphthalein mono-b-glucuronide
addition.
Materials
Q3GA was isolated from green bean pods and stored as
described [27]. Briefly, defated pods were homogenized in 70%
MeOH, the concentrated extract was fractionated on a polyamide
column and washed firstly with phosphate buffer, then with
methanol and finally with methanol/ammonia (99.5:0.5 v/v) to
elute the acidic flavonols (e.g. glucuronides). The glucuronide was
purified by semipreparative-HPLC. Q3’S was synthesized by an
adaptation of the method described by Jones et al. [28]. Briefly,
dehydrated quercetin was dissolved in dioxane and allowed to
react at 40uC for 90 min with a 10-fold molar excess of sulfur
trioxide-N-triethylamine complex under a nitrogen atmosphere.
Precipitated products of sulfation were redissolved in 10%
methanol in water and the mixtures of quercetin sulfates were
fractioned on a Sephadex LH-20 column and Q3’S further
purified by semipreparative HPLC. I3GA was produced enzy-
matically using pig liver microsomal enzymes with a modification
of the methodology described by Plumb et al. [29]. Briefly, a post-
lysosomal fraction was obtained from a pig liver extract, incubated
with isorhamnetin at 37uC for 240 min, in a Hepes buffer
(25 mM, pH 5.5 and pH 7.2) or ultra-pure water, containing in
either case 10 mM MgCl2, UDP-glucuronic acid (8 mM) and
UDP-glucosamine (4 mM). I3G was isolated by semipreparative
HPLC. All other drugs were from Sigma (Tres Cantos, Madrid,
Spain).
Statistical analysis
Results are expressed as the mean 6 SEM and n describes the
number of measurements made (i.e., from different animals).
Differences between experimental groups were treated using
unpaired Student’s t-test or, for multiple comparisons, using
one-way analysis of variance followed by a Dunnett’s post hoc test.
P values,0.05 were considered statistically significant.
Results
Effects of plasma metabolites on blood pressure
SHR showed a basal MBP of 18165 mm Hg and HR of
424614 bpm. Q3GA and I3GA (1 mg/kg i.v.) progressively
reduced mean blood pressure (MBP) in SHR, while Q3’S was
without effect. This hypotensive effect induced by both metabolites
was statistically significant after 1 and 2 h, respectively, of the
metabolite injection. The maximum effects observed at 3 h were
14.961.8% and 11.461.8%, respectively (Figure 2A). No
significant changes in heart rate (HR) were observed with any
metabolite (Figure 2B). Q3GA also decreases MBP at low
concentrations (0.02 and 0.2 mg/kg) (Figure 2C), being also
without effects on HR (Figure 1D).
Time-course of the Q3GA concentrations in plasma
When SHR were treated with Q3GA, 1 mg/kg i.v., there was
an increase in the plasma concentration of this metabolite
reaching 23.261.8 mM at 1 min and decreased rapidly (,1 mM
at 30 min) (Figure 3A, 3B). Moreover, free quercetin aglycone and
I3GA was detected in plasma after Q3GA injection.
Effects of metabolites in the reactivity of mesenteric
artery
Phenylephrine induced a maximal contractile effect in mesen-
teric vessels from SHR of 19.460.9 mN (n=20). When
mesenteric arteries from SHR were incubated with the aglycones
quercetin or isorhamnetin for 30 min a significant concentration-
dependent decrease in the vasoconstrictor response to phenyleph-
rine was observed (Figure 4) while Q3GA at this time had no effect
(Figure 5A). However, when the incubation of 25 mM Q3GA was
prolonged to 1 and 2 hours a significant reduction in the
vasoconstriction induced by phenylephrine was detected
(Figure 5B and 5C).
Role of glucuronidase activity in the hypotensive and
vascular effects induced by Q3GA
To explore the possible role of deconjugation of Q3GA on the
observed effects a specific inhibitor of beta-glucuronidase (SAL)
was used, which was administered i.p. during the 3 days before the
blood pressure recordings. Interestingly, the hypotensive effect of
Q3GA was abolished in SHR treated with SAL (Figure 6A). We
confirmed the inhibitory glucuronidase activity of SAL (1 mM) in
homogenates from the mesenteric bed in in vitro conditions, by
incubating during 1 h and measuring glucuronidase activity
(Figure 6C). We also found that the inhibitory effects of Q3GA
in the contractile response induced by phenylephrine were
suppressed when mesenteric arteries were incubated with SAL
(Figure 6D), but not those of quercetin (Figure 6E).
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vascular effects induced by quercetin
The above results prompted us to analyze whether deconjuga-
tion was also required for the antihypertensive effect of orally
administered quercetin. Administration of quercetin (10 mg/Kg
using an intragastric gavage) induced a progressive decrease in
MBP and HR during 6 hours of register. These reductions were
significant, as compared to vehicle, after 2.5 h of administration,
and reached a maximum of 2864% and 1862%, respectively at
6 h (Figure 7A, 7B). Importantly, when SHR were treated with
SAL, oral quercetin was unable to induce changes in both MBP
and HR (Figure 7C, 7D). However, SAL was unable to modify the
in vitro effect of quercetin on the contractile response to
phenylephrine in isolated mesenteric arteries.
Discussion
Fruit and vegetable consumption is associated with a decrease in
blood pressure, which is an important cardiovascular risk factor
[30]. Quercetin, the most important dietary flavonol, present in
multiple fruits and vegetables, reduces blood pressure in
hypertensive animals and human after chronic consumption
[9,13,31–37]. Herein, we show for the first time that the
conjugated derivatives Q3GA and I3GA can exert antihyperten-
sive effects when administered intravenously. As previously
Figure 2. Effects of intravenous Q3GA, Q3’S, and I3GA (1 mg/kg) and Q3GA (0.02, 0.2 mg/kg) on mean arterial blood pressure (A, C)
and heart rate (B, D) measured by direct carotid artery recording in a conscious rat. Results are means 6 SEM of 4–6 experiments.
*P ,0.05 vs. saline.
doi:10.1371/journal.pone.0032673.g002
Figure 3. Concentrations of quercetin, I3GA, and Q3GA measured in plasma from SHR treated with 1 mg/kg Q3GA. (A) HPLC
chromatograms recorded at 370 nm of plasma samples taken at 1 min. (B) Time-concentration relationship. Results are means 6 SEM of 4
experiments.
doi:10.1371/journal.pone.0032673.g003
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developed with more prolonged incubations. Both the in vitro and
the in vivo effects were prevented by the b-glucuronidase inhibitor
SAL. Taken together these data strongly suggest that deconjuga-
tion is required for the effect of quercetin metabolites. Moreover,
oral quercetin reduced blood pressure by almost 30% in SHR,
being this effect persistent at least during 6 hours and, importantly,
this effect was also prevented by SAL, indicating that the sequence
of liver-intestine conjugation and local (vascular) deconjugation
processes is required for the antihypertensive effect of quercetin.
Both human and rat tissues, except for the cells lining the
intestine tract, are exposed to quercetin via the blood. However,
the free forms of quercetin and its methylated metabolite
isorhamnetin are barely detected in plasma, which raises the
question of which is/are the compound(s) responsible for the
antihypertensive activity. Because glucuronidated and sulfated
compounds are the only detectable metabolites, it is suggested that
conjugated metabolites must play a decisive role in the possible
beneficial effects [38]. Our results support this hypothesis, because
we showed that Q3GA and I3GA, the main plasma metabolites of
quercetin exerted an antihypertensive effect. Doses of Q3GA as
low as 0.02 mg/kg also significantly reduced blood pressure. In
contrast, Q3’S was without effect. Herein, we show that both
Q3GA and I3GA metabolites show a similar effect. Previous
published papers from other groups [15–18], the concentrations of
methylated forms of quercetin are in the same range or higher
than non methylated ones in rats and humans supplemented with
quercetin, suggesting that both forms may contribute to the
antihypertensive effect.
When we analyzed the time course of the antihypertensive effect
and compared it to the plasma concentrations of Q3GA we found
a clear dissociation (Fig. 2A vs Fig. 3B). In our experimental
conditions, the dose of 1 mg/kg of Q3GA intravenously induced a
peak plasma concentration of ,25 mM which is higher than that
previously reported by da Silva et al. [39] of 9.6 mM 6 h after
10 mg/kg quercetin delivered via oral gavage. However, Q3GA
rapidly disappeared from the plasma, indicating that the two
modes of administration result in a completely different pharma-
cokinetic profile. The fast decay of Q3GA concentration in plasma
is not compatible with renal excretion, suggesting that Q3GA is
metabolized, accumulated in tissues or both. In a recent in vitro
study [24], the perfusion of Q3GA through the rat mesenteric
vascular bed resulted in a partial accumulation of Q3GA in the
tissue and a progressive process of deconjugation. The resulting
aglycone was partly found in the extracellular buffer and mostly
retained intracellularly. The beta-glucuronidase inhibitor SAL
increased the tissue Q3GA and reduced the aglycone. Deconjuga-
tion by beta-glucuronidase is expected to occur intracellularly
Figure 4. Effects of (A) quercetin and (B) isorhamnetin (10 or 25 mM, incubated for 30 min) on the contractile responses to
phenylephrine in mesenteric resistance arteries. Control is treated with vehicle (DMSO). Results are means 6 SEM of 4–8 experiments.
*P ,0.05 and **P,0.01 vs. control.
doi:10.1371/journal.pone.0032673.g004
Figure 5. Effects of Q3GA (10 or 25 mM) on the contractile responses to phenylephrine in mesenteric resistance arteries, after 30 (A),
60 (B) or 120 (C) min of incubation. Results are means 6 SEM of 4–8 experiments. * P,0.05 and **P,0.01 vs. control.
doi:10.1371/journal.pone.0032673.g005
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microsomal fraction. Therefore, the aglycone is formed within
the vessel and probably in the cytosol of smooth muscle cells where
it is expected to interact with its targets to exert vascular smooth
muscle relaxation. The most plausible targets for this effect include
the protein kinases involved in the regulation of myosin-actin
interactions including protein kinase C, myosin light chain kinase
or Rho kinase and possibly potassium channels [8,9,40,41].
Quercetin aglycone released to the plasma is likely to be rapidly
re-conjugated in the liver explaining its low levels.
The vasorelaxant effects of quercetin and related metabolites
have been widely assessed in vitro in aorta and perfused mesenteric
bed [7,8,42]. Increased alpha-adrenergic response in small
mesenteric arteries has been involved in increased blood pressure
in SHR [43,44]. As expected, both quercetin and isorhamnetin
incubated during 30 min, inhibited the contractile response
induced by the alpha-adrenergic receptor agonist phenylephrine.
In the same experimental conditions, Q3GA did not modify this
response. These results are consistent with previous data showing
that conjugation of flavonoids results in a decreased biological
activity [45,46] and that conjugated metabolites have no direct
vasorelaxant effect in isolated rat aorta at physiological concen-
trations [21]. However, when small mesenteric arteries were
incubated for 1 or 2 h with Q3GA, at 25 mM, the vasoconstriction
induced by phenylephrine was significantly reduced, suggesting
that quercetin accumulates in this vascular bed and it is
responsible of the reduced vascular tone. A similar scenario has
been described previously in which quercetin metabolites in
circulating blood can permeate through the injured/activated
endothelial cells and interact with the subintimal cells, such as the
macrophages and smooth muscle cells [22,47]. Deconjugation of
the glucuronide metabolites of the flavonoids by increased b-
glucuronidase activity at the site of inflammation has been
suggested as a plausible mechanism for the protective effects of
flavonoids in vivo [23,48]. Accordingly, the release of b-glucuron-
idase is considered an index of lysosomal membrane integrity [49].
In fact, mesenteric bed from SHR expresses b-glucuronidase and
its activity was significantly inhibited by SAL, a specific inhibitor.
Vascular tissues from SHR showed increased expression of
proinflammatory markers, altered endothelial function, and
increased macrophage infiltration than normotensive animals
[50,51], which could facilitate metabolite accumulation and
deconjugation in this inflamed tissue. In our experiments, the
antihypertensive effect of Q3GA was abolished by b-glucuronidase
inhibition, which suggests that this effect requires b-glucuronidase-
mediated deconjugation. Moreover, the inhibitory effect in the
contractile response to phenylephrine in mesenteric arteries
induced by Q3GA was also suppressed by SAL, showing that
Q3GA requires deconjugation to exert this inhibitory effect.
Given the role of b-glucuronidase in the effects of Q3GA we
aimed to analyze whether it was also relevant for the antihyper-
tensive effect of quercetin. Surprisingly, despite several chronic
studies, to our knowledge the effects of acute oral quercetin
administration on blood pressure in hypertensive animals had not
been studied. We found a slow developing but long lasting
antihypertensive effect. Remarkably, the effects of oral quercetin
were also abolished by b-glucuronidase inhibition with SAL.
However, as expected, the in vitro effects of quercetin were
Figure 6. Effects of Q3GA in arterial blood pressure (A) and heart rate (B) in SHR treated with SAL (10 mg/rat/day for 3 days) or
vehicle (means ± SEM of 4 experiments). Panel (C) shows the bands of b-glucuronidase expression by Western blot and the b-glucuronidase
activity and its inhibition by SAL (1 mM) in vascular bed homogenates (means 6 SEM of 8 experiments). (D) Effects of Q3GA (25 mM) on the
contractile responses to phenylephrine in mesenteric arteries after 120 min in the presence of SAL (1 mM) (means 6 SEM of 5 experiments). (E)
Effects of quercetin (25 mM) on the contractile responses to phenylephrine in mesenteric arteries after 30 min in the presence of SAL (1 mM) (means
6 SEM of 5 experiments). * P,0.05 and **P,0.01 vs. control.
doi:10.1371/journal.pone.0032673.g006
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activity of quercetin is dependent on the conjugation-deconjuga-
tion processes. Although decreased glucuronidation often results in
increased activity and/or toxicity of drugs, paradoxically,
glucuronidation seems to be required for the activity of quercetin.
Therefore, glucuronidation may protect quercetin from its
metabolism via other pathways and help to carry the flavonoid
to the tissues where the free aglycone is released [52]. Our data
also suggest that polymorphisms of UDP-glucuronosyltransferases
(encoded by the UGT1 and UGT2 loci), which are common in
humans [53] and changes in the b-glucuronidase activity, might
result in a variable response to quercetin.
In conclusion, we show that glucuronides of quercetin and its
methylated metabolite isorhamnetin are involved in the antihy-
pertensive response of oral quercetin, which might be related, at
least in part, by the inhibitory effect in the a-adrenergic-induced
hypercontractile response in resistance arteries. Quercetin could
be initially inactivated by a conjugation metabolism during
absorption and then safely be delivered to inflamed arterial wall,
and the recruited metabolites are incorporated and converted to
the aglycone in vascular smooth muscle cells and exert the
inhibitory activity on vascular tone. These results are in agreement
with the hypothesis that flavonoid glucuronides appear to serve as
plasma transport metabolites to target cells rather than solely as
excretion.
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